JY
RNAZ icon

Jeff Yass’s TransCode Therapeutics RNAZ Stock Holding History

Jeff Yass’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26
Closed -$24.4K – 12879
2024
Q2 		$24.4K Buy
+26
New +$23.1K ﹤0.01% 11613
2024
Q1 		– Hold
0
– -$1.81K – 13170
2023
Q4 		– Hold
0
– – – 12178
2023
Q3 		– Hold
0
– -$31.4K – 12824
2023
Q2 		– Hold
0
– – – 11499
2023
Q1 		– Hold
0
– -$14K – 13349
2022
Q4 		– Hold
0
– – – 11860

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Jeff Yass's RNAZ Position: Q3 2024 in Review

Jeff Yass sold out of TransCode Therapeutics (RNAZ) in Q3 2024, closing a stake of 26 shares — an estimated $24.4K sold.

Jeff Yass first reported a position in RNAZ in Q2 2024 and held it in 1 quarter. The position peaked at $24.4K in Q2 2024. 7 funds tracked by Wall St. Rank hold RNAZ as of Q3 2024.

  • Jeff Yass reported no remaining TransCode Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 26 TransCode Therapeutics shares in Q3 2024, an estimated $24.4K.
  • Jeff Yass first reported a position in TransCode Therapeutics in Q2 2024 and held it in 1 quarter.
  • Jeff Yass's TransCode Therapeutics position peaked at $24.4K in Q2 2024.
  • 7 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.